A phase I/II study of chemotherapy using S-1, Oxaliplatin plus Irinotecan for unresectable pancreatic cancer

Not Applicable

• Conditions: unresectable pancreatic cancer

• Registration Number: JPRN-UMIN000014471
• Lead Sponsor: Department of Gastroenterology Kitasato University School of Medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2014-07-07
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 25

Inclusion Criteria

Not provided

Exclusion Criteria

1.Patients with contraindication for the medication of S-1, L-OHP and Irinotecan 2.History of serious drug hypersensitivity or a history of drug allergy 3.Pregnancy 4.Active infection 5.Severe complications 6.Peripheral neuropathy 7.Serious diarrhea 8.Intestinal pneumonitis or pulmonary fibrosis 9.Much ascites or pleural effusion or pericardial effusion 10.Active double cancer 11.Symptomatic brain metastasis 12.Regular use of frucitocin, fenitoin or warfarin 13.Having UGT1A1*6/*6, UGT1A1*28/*28, or UGT1A1*6/*28 gene 14.HBV carrier who has to take nucleotide analogues during chemotherapy 15.Inappropriate for this study judged by the attending physician

Study & Design

• Study Type: Interventional
• Study Design: Not specified